SK pharmteco: Company Research Report

Company Overview

• Name: SK pharmteco

• Mission of the Company: Deliver integrated CDMO services with a dedication to life-saving therapies; change the world through dedication to health and happiness via innovative medicine.

• Founded: Built on 80 years of experience (founded in 1942).

• Key People: Joyce Fitzharris (President of SK pharmteco, Small Molecule, Europe), Patrick Mahieux (President of Cell and Gene, Europe), Chief Communications Consultant: Keith Bowermaster.

• Headquarters: Rancho Cordova, California, USA.

• Global Operations: Facilities are located in the USA, Ireland, France, and Korea.

• Number of Employees: Approximately 2,000 highly skilled and talented workers.

• Revenue: No information is available.

• Known For: Specializes in the manufacturing of active pharmaceutical ingredients (APIs), cell and gene therapy technologies, registered starting materials, and analytical services for the pharmaceutical industry worldwide.

Products and Services

Products Offered:

1. Active Pharmaceutical Ingredients (APIs):

• High-Level Description: Manufacturing of APIs and registered intermediates across various locations worldwide.

• Key Features: Known for handling all scales of production with compliance to cGMP practices.

2. Cell and Gene Therapy Technologies:

• High-Level Description: Specialized technologies for advanced therapies.

• Key Features: Includes CGT process development and analysis, plasmid DNA manufacturing, and viral vector production.

3. Analytical Services:

• High-Level Description: Contractual services for method development, validation, and quality testing.

• Key Features: Supports various pharmaceutical formulations while maintaining CGMP standards.

4. Advanced Manufacturing Techniques:

• Energetic Chemistry, Continuous Flow Processing, Chromatography, and High Potency: Various advanced technologies for efficient and safe manufacturing.

• Key Features: Includes continuous processing and high-potency manufacturing capabilities, such as handling highly potent compounds and chromatographic separations.

Recent Developments

• Expansion & Investments:

• SK pharmteco announced a $260 million investment to expand small molecule and peptide production with a new facility in Sejong, South Korea.

• Strategic Partnerships:

• Collaborative agreement with AaviGen to manufacture the AVG-101 gene therapy product for heart failure.

• Leadership Appointments:

• Joyce Fitzharris was appointed as Chairperson of BioPharmaChem Ireland, which involves leading industry engagement in Ireland.

Global Presence and Facilities

• Manufacturing and R&D Sites:

• United States: Multiple sites including California, Texas, and Pennsylvania focused on manufacturing and R&D.

• Europe: Ireland and France for small molecule and cell and gene therapy facilities.

• Korea: Manufacturing and R&D site in Sejong and Daejeon.

• Capacity and Capabilities:

• Diverse and large-scale production facilities with a focus on regulatory compliance across U.S., EU, Japan, and Korea standards.

Conclusion

SK pharmteco stands as a comprehensive CDMO partner with a substantial global footprint. Their strong focus on innovative solutions, regulatory compliance, strategic partnerships, and recent expansions positions them as a leader in operational excellence and delivery of life-saving pharmaceutical solutions globally. The company's commitment to growth and strategic development ensures they meet the complex demands of the biopharmaceutical industry.

Contact information and further details about SK pharmteco can be accessed through their [official website](http://www.skpharmteco.com).